Drug Profile
Research programme: Duchenne muscular dystrophy therapeutics - DMD Therapeutics
Alternative Names: DMD-813Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator DMD Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Duchenne muscular dystrophy
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA
- 24 Feb 2017 Preclinical trials in Duchenne muscular dystrophy in USA (unspecified route)